U.S. Sen. Dianne Feinstein (D-CA) (R) and U.S. Sen. Chuck Grassley (R-IA) talk during Senate Caucus on International Narcotics Control hearing on Capitol Hill (Photo by Mark Wilson/Getty Images)
Over the past few months, from local community halls to Capitol Hill, one thing has been made clear: there is an outcry of support in favor of more research on CBD and medical marijuana. Proponents of CBD oil state that removing these barriers to research is the only clear way to market something so significant to families around the world.
Earlier this year, Democrat Sen. Diane Feinstein (CA) and Republican Sen. Charles Grassley (IA) urged the Obama administration to “definitively determine if CBD has scientific and medical benefits,” and to “look at expanding compassionate access programs where possible, to benefit as many children as possible.”
Recently, support has also come out from the director of the US National Institute on Drug Abuse (NIDA), Nora Volkow. Volkow believes that cannabidiol (CBD) – a nonpsychotropic cannabinoid – is “a safe drug with no addictive effects.” In a column with The Huffington Post, she further stated that“[P]reliminary data suggest that it may have therapeutic value for a number of medical conditions.”
With all of the talk going on around the country, is there any action behind these promises? […]